The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2013Alpha-Synuclein Effects on Fusion Pore Expansion and Protein Secretion
Objective/Rationale:
Alpha-synuclein, implicated in Parkinson’s disease, is normally expressed in nerve terminals, from which neurotransmitters are released by fusion of their granule membrane with the... -
Therapeutic Pipeline Program, 2013Synthetic Nurr1 Ligands as Novel Neuroprotective Therapeutics to Treat Parkinson’s Disease
Objective/Rationale:
The orphan nuclear receptor Nurr1 plays a critical role in the development and maintenance of midbrain dopamine neurons. Recent research also shows that it protects... -
Therapeutic Pipeline Program, 2013Novel, Small Molecule Transforming Growth Factor Beta Agonist
Objective/Rationale:
This project aims to develop a small molecule-based therapeutic targeting transforming growth factor beta (TGFB) signaling for the treatment of Parkinson’s disease (PD... -
LRRK2 Pharmacodynamic Assays, 2013Measuring LRRK2 Cellular Function in Parkinson’s iPSC-Derived Dopaminergic Neurons
Objective/Rationale:
We aim to develop a time-lapse, imaging, pharmacodynamic assay for measuring LRRK2 cellular function in dopaminergic (DA) neurons derived from human induced... -
Research Grant, 2013Alpha-Synuclein-Expression-Lowering Therapeutics: Initial Pre-Clinical Development
Objective/Rationale:
Increased dosage of the alpha-synuclein gene is linked to Parkinson’s disease (PD). Out of 1,126 FDA-approved compounds and health supplements screened, we identified... -
Rapid Response Innovation Awards, 2013BL-OG: A Novel, Minimally-Invasive and Homeostatic Method for Selective Regulation of Neural Dynamics in the Subthalamic Nucleus
Objective/Rationale:
Altered neural activity in the subthalamic nucleus (STN) is believed to be key to Parkinson’s disease. Accordingly, deep-brain stimulation (DBS) delivered to the STN...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.